
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/305667/publications.pdf Version: 2024-02-01



RRAD H ROVIN

#	Article	IF	CITATIONS
1	Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis and nephritis assessment with rituximab study. Arthritis and Rheumatism, 2012, 64, 1215-1226.	6.7	1,083
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
3	Update on Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 825-835.	4.5	560
4	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine, 2020, 383, 1117-1128.	27.0	506
5	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
6	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
7	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2070-2080.	13.7	268
8	Urine Chemokines as Biomarkers of Human Systemic Lupus Erythematosus Activity. Journal of the American Society of Nephrology: JASN, 2005, 16, 467-473.	6.1	236
9	Update on Lupus Nephritis: Core Curriculum 2020. American Journal of Kidney Diseases, 2020, 76, 265-281.	1.9	228
10	Predictors of Longâ€Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‣upus Nephritis Cohort. Arthritis and Rheumatology, 2015, 67, 1305-1313.	5.6	224
11	A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney International, 2019, 95, 219-231.	5.2	208
12	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
13	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	6.1	174
14	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Science and Medicine, 2015, 2, e000123-e000123.	2.7	155
15	B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 100-107.	0.9	154
16	Histologic versus clinical remission in proliferative lupus nephritis. Nephrology Dialysis Transplantation, 2017, 32, 1338-1344.	0.7	152
17	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
18	A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney International, 2018, 94, 788-794.	5.2	110

#	Article	IF	CITATIONS
19	MG53-mediated cell membrane repair protects against acute kidney injury. Science Translational Medicine, 2015, 7, 279ra36.	12.4	103
20	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1595-1602.	4.5	103
21	Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212599.	0.9	98
22	Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrology Dialysis Transplantation, 2014, 29, 2228-2234.	0.7	93
23	Renal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 279-284.	4.5	92
24	Biomarkers for Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1858-1865.	4.5	90
25	Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney International, 2021, 99, 1487.	5.2	90
26	Lupus Nephritis: The Evolving Role of Novel Therapeutics. American Journal of Kidney Diseases, 2014, 63, 677-690.	1.9	87
27	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Annals of the Rheumatic Diseases, 2022, 81, 496-506.	0.9	87
28	A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney International, 2016, 90, 493-501.	5.2	80
29	A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney International, 2022, 101, 403-413.	5.2	80
30	Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. Clinical Chemistry, 2017, 63, 1515-1526.	3.2	76
31	Kidney biopsy–based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney International, 2020, 97, 156-162.	5.2	72
32	Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney International, 2020, 98, 233-234.	5.2	67
33	A reference tissue atlas for the human kidney. Science Advances, 2022, 8, .	10.3	67
34	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
35	Staphylococcus-Related Glomerulonephritis and Poststreptococcal Glomerulonephritis: Why Defining "Post―Is Important in Understanding and Treating Infection-Related Glomerulonephritis. American Journal of Kidney Diseases, 2015, 65, 826-832.	1.9	65
36	Staphylococcus Infection–Associated GN – Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 39-49.	4.5	65

#	Article	IF	CITATIONS
37	COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?. Kidney International, 2021, 100, 959-965.	5.2	65
38	Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2020, 31, 1335-1347.	6.1	63
39	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	2.7	62
40	A multimodal and integrated approach to interrogate human kidney biopsies with rigor and reproducibility: guidelines from the Kidney Precision Medicine Project. Physiological Genomics, 2021, 53, 1-11.	2.3	59
41	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. Arthritis Care and Research, 2016, 68, 1003-1011.	3.4	54
42	Biomarker discovery in human SLE nephritis. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 187-93.	0.7	54
43	Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 147-153.	4.5	50
44	Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 47-53.	4.5	49
45	Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. Nephrology Dialysis Transplantation, 2017, 32, i71-i79.	0.7	46
46	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	5.6	45
47	Antiâ^'PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. Kidney International Reports, 2019, 4, 1152-1160.	0.8	44
48	Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nature Reviews Nephrology, 2016, 12, 205-216.	9.6	43
49	Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy. Kidney Research and Clinical Practice, 2017, 36, 387-392.	2.2	43
50	New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Antiâ€DNA. Arthritis and Rheumatology, 2017, 69, 487-493.	5.6	42
51	Early experience with COVID-19 in kidney transplantation. Kidney International, 2020, 97, 1074-1075.	5.2	41
52	The lupus nephritis management renaissance. Kidney International, 2022, 101, 242-255.	5.2	40
53	Cyclopentenone Prostaglandins Inhibit Cytokine-Induced NF-κB Activation and Chemokine Production by Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 1659-1667.	6.1	39
54	Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Science and Medicine, 2015, 2, e000112-e000112	2.7	38

#	Article	IF	CITATIONS
55	Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. Proteomics - Clinical Applications, 2015, 9, 1012-1020.	1.6	37
56	Why Target the Gut to Treat IgA Nephropathy?. Kidney International Reports, 2020, 5, 1620-1624.	0.8	37
57	B-cell therapy in lupus nephritis: an overview. Nephrology Dialysis Transplantation, 2019, 34, 22-29.	0.7	35
58	The Kidney Biopsy in Lupus Nephritis. Rheumatic Disease Clinics of North America, 2014, 40, 537-552.	1.9	33
59	Molecular characterization of the human kidney interstitium in health and disease. Science Advances, 2021, 7, .	10.3	33
60	Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. Translational Research, 2017, 182, 1-13.	5.0	29
61	Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2020, 35, 2123-2129.	0.7	28
62	Validation of the Lupus Nephritis Clinical Indices in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 195-202.	3.4	27
63	Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 244-254.	5.6	27
64	Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). Kidney International Reports, 2019, 4, 1633-1637.	0.8	26
65	Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis. Kidney International Reports, 2020, 5, 1066-1068.	0.8	26
66	The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. Advances in Chronic Kidney Disease, 2019, 26, 360-368.	1.4	25
67	Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. Nephrology Dialysis Transplantation, 2019, 34, 1197-1206.	0.7	24
68	Rethinking Lupus Nephritis Classification on a Molecular Level. Journal of Clinical Medicine, 2019, 8, 1524.	2.4	21
69	Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
70	Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. Journal of Clinical Medicine, 2021, 10, 626.	2.4	19
71	Can We Personalize Treatment for Kidney Diseases?. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1670-1676.	4.5	18
72	Oral Warfarin and the Thrombin Inhibitor Dabigatran Increase Blood Pressure in Rats: Hidden Danger of Anticoagulants?. American Journal of Hypertension, 2015, 28, 182-189.	2.0	18

#	Article	IF	CITATIONS
73	Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. Kidney Medicine, 2019, 1, 51-56.	2.0	18
74	Prediction models of treatment response in lupus nephritis. Kidney International, 2022, 101, 379-389.	5.2	18
75	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. American Journal of Physiology - Renal Physiology, 2021, 321, F505-F516.	2.7	16
76	Of Mice and Men: The Relevance of the Mouse to the Study of Human SLE. Immunologic Research, 2001, 24, 211-224.	2.9	15
77	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	2.7	15
78	Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy. Transplantation, 2019, 103, e52-e53.	1.0	15
79	Development of a Set of Lupusâ€5pecific, Ambulatory Care–Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. Arthritis Care and Research, 2021, 73, 146-157.	3.4	15
80	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
81	The cell membrane repair protein MG53 modulates transcription factor NF-κB signaling to control kidney fibrosis. Kidney International, 2022, 101, 119-130.	5.2	14
82	Expert Perspective: An Approach to Refractory Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 915-926.	5.6	14
83	Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney International Reports, 2018, 3, 1057-1063.	0.8	13
84	Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 1168-1175.	0.7	13
85	Induction Therapy for Lupus Nephritis: the Highlights. Current Rheumatology Reports, 2018, 20, 60.	4.7	13
86	Induction and maintenance therapy of lupus nephritis: an obituary. Kidney International, 2021, 99, 288-291.	5.2	13
87	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thrombosis Research, 2021, 201, 50-59.	1.7	13
88	MG53 protects against contrast-induced acute kidney injury by reducing cell membrane damage and apoptosis. Acta Pharmacologica Sinica, 2020, 41, 1457-1464.	6.1	13
89	A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. Frontiers in Immunology, 2021, 12, 621039.	4.8	11
90	Oral Cyclophosphamide Is on the Verge of Extinction as Therapy for Severe Autoimmune Diseases (Especially Lupus): Should Nephrologists Care?. Nephron Clinical Practice, 2010, 117, c8-c14.	2.3	10

#	Article	IF	CITATIONS
91	Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue. Journal of Visualized Experiments, 2020, , .	0.3	9
92	Beyond anemia: hepcidin, monocytes and inflammation. Biological Chemistry, 2013, 394, 1-10.	2.5	8
93	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000308.	2.7	8
94	Do kidneys grow old gracefully?. Kidney International, 2020, 97, 40-41.	5.2	8
95	Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy. Kidney International Reports, 2021, 6, 2653-2660.	0.8	8
96	Targeting B-cells in lupus nephritis: should cautious optimism remain?. Nephrology Dialysis Transplantation, 2013, 28, 7-9.	0.7	7
97	The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 1394-1398.	6.1	7
98	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
99	Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. CKJ: Clinical Kidney Journal, 2015, 8, 492-502.	2.9	6
100	Advances and Challenges on New Therapies and Clinical Targets of Acute Kidney Injury. Toxicologic Pathology, 2018, 46, 925-929.	1.8	5
101	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.	0.8	5
102	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	5.2	4
103	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
104	Bath Salts: A Newly Recognized Cause of Acute Kidney Injury. Case Reports in Nephrology, 2012, 2012, 1-5.	0.4	3
105	A78: Urine Biomarkers Role in Predicting the Future Development of Renal Functional Loss With Lupus Nephritis in Children and Adults. Arthritis and Rheumatology, 2014, 66, S111-S111.	5.6	3
106	Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg), 2021, 25, 96-119.	0.4	3
107	Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression. Journal of Clinical Medicine, 2021, 10, 793.	2.4	3
108	MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	3

#	Article	IF	CITATIONS
109	A challenge to the kidney community by a man-made crisis. Kidney International, 2022, 101, 854-855.	5.2	3
110	Controversies in Systemic Lupus Erythematosus 2021. Journal of Clinical Rheumatology, 2022, 28, 229-233.	0.9	3
111	Kidney International celebrates the 60th anniversary of the International Society of Nephrology. Kidney International, 2019, 96, 1248-1249.	5.2	2
112	Response to: †Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler. Annals of the Rheumatic Diseases, 2019, 78, e34-e34.	0.9	2
113	Response to †Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al. Annals of the Rheumatic Diseases, 2020, 79, e66-e66.	0.9	2
114	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney International Reports, 2020, 5, 1302-1305.	0.8	2
115	Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients. Scientific Reports, 2020, 10, 20202.	3.3	2
116	The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. Kidney International Reports, 2021, 6, 2105-2113.	0.8	2
117	Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2018, 315, F1484-F1492.	2.7	1
118	Response to: â€~Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al. Annals of the Rheumatic Diseases, 2019, 78, e77-e77.	0.9	1
119	Response to: †Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels <i>et al</i> . Annals of the Rheumatic Diseases, 2019, 78, e49-e49.	0.9	1
120	A tolvaptan skeptic repents. Kidney International, 2020, 98, 293.	5.2	1
121	LB001EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
122	Kidney International and the COVID-19 infection. Kidney International, 2020, 97, 823.	5.2	1
123	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. Kidney International, 2021, 99, 2-4.	5.2	1
124	Looking back and moving forward. Kidney International, 2021, 99, 787-790.	5.2	1
125	The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. Kidney International, 2021, 99, 811-813.	5.2	1
126	FC 034SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1

#	Article	IF	CITATIONS
127	The Use of Serological Tests in the Care of Patients with Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 305-307.	4.5	1
128	Membranoproliferative Glomerulonephritis With Changing Immunofluorescence Pattern. Kidney International Reports, 2022, 7, 1123-1127.	0.8	1
129	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.8	1
130	Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study. Kidney International Reports, 2022, , .	0.8	1
131	Reply. Arthritis and Rheumatology, 2017, 69, 1507-1508.	5.6	0
132	Reply. Arthritis and Rheumatology, 2017, 69, 2247-2248.	5.6	0
133	Al-06â€Lupus nephritis is linked to dysbiosis, increased gut leakiness and immunity to an intestinal commensal lachnospiracaea species. , 2018, , .		0
134	Response to: â€~Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al. Annals of the Rheumatic Diseases, 2019, 78, e51-e51.	0.9	0
135	The authors reply. Kidney International, 2019, 95, 992-993.	5.2	0
136	Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni <i>et al</i> . Annals of the Rheumatic Diseases, 2019, 78, e47-e47.	0.9	0
137	Response to: â€~ANA testing in "real lifeâ€â€™ by Infantino <i>etal</i> . Annals of the Rheumatic Diseases, 2020, 79, e4-e4.	0.9	0
138	Response to: "Antinuclear autoantibodies: discordance among four different assays―by Pacheco <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e7-e7.	0.9	0
139	Response to: â€~Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro. Annals of the Rheumatic Diseases, 2020, 79, e33-e33.	0.9	0
140	In this issueâ \in "2020 draws to a close. Kidney International, 2020, 98, 1361.	5.2	0
141	Variability in the B cell–receptor repertoire across immune-mediated diseases. Kidney International, 2020, 98, 536-538.	5.2	0
142	Letter to the Editor. Kidney International Reports, 2020, 5, 2121.	0.8	0
143	Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab. Kidney International Reports, 2020, 5, 951-954.	0.8	0
144	The authors reply. Kidney International, 2020, 97, 807.	5.2	0

#	Article	IF	CITATIONS
145	The authors reply. Kidney International, 2021, 99, 1242.	5.2	0